

Metabolic Inhibitors

A Comprehensive Treatise

edited by

R. M. HOCHSTER

J. H. QUASTEL

Volume I

Metabolic Inhibitors

A Comprehensive Treatise

edited by

R. M. Hochster

*Biochemistry Section
Microbiology Research Institute
Canada Department of Agriculture
Ottawa, Canada*

J. H. Quastel

*Department of Biochemistry
McGill University and the
McGill-Montreal General Hospital
Research Institute
Montreal, Canada*

Volume I



Academic Press • New York • London • 1963

COPYRIGHT © 1963, BY ACADEMIC PRESS, INC.

ALL RIGHTS RESERVED.

NO PART OF THIS BOOK MAY BE REPRODUCED IN ANY FORM,
BY PHOTOSTAT, MICROFILM, OR ANY OTHER MEANS, WITHOUT
WRITTEN PERMISSION FROM THE PUBLISHERS.

ACADEMIC PRESS INC.

111 Fifth Avenue, New York 3, New York

United Kingdom Edition published by

ACADEMIC PRESS INC. (LONDON) LTD.

Berkeley Square House, London W.1

LIBRARY OF CONGRESS CATALOG CARD NUMBER: 63-12924

PRINTED IN THE UNITED STATES OF AMERICA

Contributors

Numbers in parentheses indicate the page on which the author's contribution appears.

E. P. ANDERSON (239), *National Cancer Institute, National Institutes of Health, Bethesda, Maryland*

S. B. BARKER (535), *Department of Pharmacology, University of Alabama Medical Center, Birmingham, Alabama*

R. W. BROCKMAN (239), *Kettering-Meyer Laboratory, Southern Research Institute, Birmingham, Alabama*

HARRY P. BROQUIST (481), *Department of Dairy Science, University of Illinois, Urbana, Illinois*

WILLIAM GILBERT CLARK (315), *Psychopharmacology Research Laboratories, Veterans Administration Hospital, Sepulveda, California*

J. S. COLTER (287), *Biochemistry Department, University of Alberta, Edmonton, Alberta, Canada*

J. B. DAVENPORT (173), *Low Temperature Research Station, University of Cambridge, Cambridge, England¹*

R. I. DORFMAN (567), *The Worcester Foundation of Experimental Biology, Shrewsbury, Massachusetts*

GERTRUDE B. ELION (215), *Wellcome Research Laboratories, Burroughs-Wellcome & Company, Inc., Tuckahoe, New York*

K. A. O. ELLEM (287), *Wistar Institute, Philadelphia, Pennsylvania²*

SIDNEY FARBER (75), *The Children's Cancer Research Foundation; and Department of Pathology, Harvard Medical School at The Children's Hospital; Boston, Massachusetts*

GEORGE E. FOLEY (75), *Laboratories of Microbiology, The Children's Cancer Research Foundation; and Department of Pathology, Harvard Medical School; Boston, Massachusetts*

¹ Present address: Division of Food Preservation, C.S.I.R.O., North Ryde, New South Wales, Australia.

² Present address: Department of Bacteriology, University of Sydney, Sydney, Australia

- J. GREEN (407), *Walton Oaks Experimental Station, Vitamins Ltd., Tadworth, Surrey, England*
- GEORGE H. HITCHINGS (215), *The Wellcome Research Laboratories, Burroughs Wellcome & Company, Inc., Tuckahoe, New York*
- R. M. HOCHSTER (131), *Biochemistry Section, Microbiology Research Institute, Canada Department of Agriculture, Ottawa, Canada*
- THOMAS H. JUKES (481), *Agricultural Division, American Cyanamid Company, Princeton, New Jersey*
- I. ARTHUR MIRSKY (383), *Department of Clinical Science, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania*
- EDWARD J. MODEST (75), *Laboratories of Organic Chemistry, Children's Cancer Research Foundation; Department of Pathology, Children's Medical Center and Harvard Medical School; Boston, Massachusetts*
- P. G. SCHOLEFIELD (153), *McGill-Montreal General Hospital Research Institute, Montreal, Quebec, Canada*
- WILLIAM SHIVE (1), *Department of Chemistry, University of Texas, Austin, Texas*
- CHARLES G. SKINNER (1), *Clayton Foundation Biochemical Institute and Department of Chemistry, The University of Texas, Austin, Texas*
- D. W. WOOLLEY (445), *Department of Biochemistry, The Rockefeller Institute, New York, New York*

Preface and Introduction

Information on inhibitors of metabolic processes or enzyme systems is widely distributed in the scientific literature today. Such inhibitors are being used in all fields of enzyme investigations or in studies of cell metabolism generally, where they are being applied to an increasing extent in a variety of experimental as well as practical aspects ranging from medicine to agriculture. While many investigators use inhibitors in the course of their work, not all are aware of the relevant but scattered information concerning them nor of the full implications of the results obtained through their use. There is not, at the present time, a truly comprehensive treatise devoted to the many aspects of the properties of metabolic inhibitors as we know them today, although certain specific areas have received attention from time to time (as in the *Annual Review of Biochemistry* or *Annual Review of Pharmacology*) and much valuable material may be found in the various monographs, textbooks, and treatises devoted to the properties of enzymes.

It is proposed, in these two volumes of "Metabolic Inhibitors", to provide a comprehensive and authoritative presentation of the properties of metabolic inhibitors which are judged to be of value to the research worker in the various fields of biological chemistry as well as to the advanced student. Moreover, the volumes are intended to be broad in their coverage and to include information that may be of service not only to biochemists and medical research workers but also to others working in the microbiological, botanical, and other agricultural fields. It is hoped that these volumes will present the first comprehensive treatise on the uses of the wide variety of substances which interfere with (and usually retard) metabolic and enzymic processes. The emphasis on the whole is on the inhibitor rather than on the metabolic or enzymic system which is affected.

It is the Editors' hope that these volumes will become a stimulus to further research, that they may help to delineate those areas of knowledge which require further clarification, and that they may emphasize the gaps which exist in our present state of knowledge. "Metabolic Inhibitors" will include data which should enable the investigator to identify the point of attack by an inhibitor of a given metabolic process, whether it be a specific enzyme or a connecting link in a multienzyme system. The importance of

inhibitor techniques in throwing useful light on many biological processes will be emphasized and their application to subjects of great practical value, such as are found in pharmacology, in medicine, or in agriculture, pointed out.

The subject of inhibition kinetics is not covered in "Metabolic Inhibitors" as it is felt that this very specialized area of the field has been exceedingly well documented in a number of recent publications (1-8) which are readily accessible. Duplication would serve no really useful purpose.

SOME HISTORICAL NOTES

In the realm of pharmacology or physiology concerned with the mechanism of drug action increasing attention is being paid to the behavior of enzymes. This subject has grown enormously within the last two decades. A glance at the early literature on the effects of poisons and inhibitors of biological systems reveals much empirical knowledge concerning the effects of a wide variety of inorganic substances (e.g., fluoride, cyanide, arsenite, hydrogen sulfide, salts of mercury, lead, iron, barium) and of organic materials (e.g., antiseptics and narcotics such as toluene, chloroform, chloral, dye-stuffs) on enzyme preparations of various degrees of purity and on cell life in general. The respiratory inhibitors carbon monoxide and cyanide provided much valuable early knowledge in the development of this field.

A very considerable stimulus to the study of the mode of action of biological inhibitors came with the recognition of the principle of competitive inhibition. This principle is widely accepted today as an aid to the understanding of the mechanisms of action of many drugs and as a means for the investigation of problems of chemotherapy. A number of reviews have been written on the subject (9-13).

The modern conception of the principle of competitive inhibition by structural analogues arose as a result of investigations (14) carried out with the dehydrogenase systems of bacteria. It was concluded (14-16) that the active center of an enzyme is so constituted that it may combine with a variety of substances all possessing a particular type of chemical structure but that, of all the molecules having this structure, only a few are actually substrates, i.e., they are capable of being activated to undergo subsequent chemical change. It followed from this conclusion that many molecules may compete with each other and with the substrate for attachment to an enzyme. Thus the presence of the structural analogue of the substrate of the particular enzyme would have the effect of diminishing the activity of that enzyme toward the substrate. An important example of this phenomenon was the competitive inhibitory effect of malonate on succinic dehydrogenase

(14). It was evident that structural analogues, which would combine with an enzyme but which would not be activated, could act as competitive antagonists to the substrate if they were present in the enzyme system at sufficiently high concentrations. The magnitude of the inhibition thus obtained would be dependent on the relative affinities of analogues and of substrates to the enzyme.

That a structural analogue may also act as an antimetabolite in the modern sense of the word was demonstrated quite early (17). It was shown that the proliferation of *Escherichia coli* cells in a medium containing fumarate as the sole source of carbon was greatly inhibited if malonate was added to the medium. Although malonate acted as an inhibitor of bacterial growth in this system it was not a cell poison, for it had no inhibitory effects under conditions where the oxidation of fumarate was not required to provide the bacteria with carbon for biosynthetic purposes.

The inhibitory effect of malonate on succinic dehydrogenase has proven to be a most valuable tool in studies of the respiratory systems of living cells. The phenomenon was fundamental to the studies of Szent-Györgyi (18) on fumaric acid catalysis in muscle respiration and to the work of Krebs (19) and later workers on the tricarboxylic acid cycle.

The practical value of the principle of competitive inhibition was not generally appreciated until 1940 when it was reported (20) that the bacteriostatic action of sulfanilamide and related sulfonamide drugs, which had come into prominence following the initial discovery of the antibacterial activity of Prontosil, was reversed competitively by *p*-aminobenzoate. The competitive relationship, taken together with the similarity in chemical structure between sulfanilamide and the antagonist as well as the high activity of the latter, led to a working hypothesis concerning the mode of action of sulfonamides. It was suggested that *p*-aminobenzoate is an essential growth factor for bacteria and that sulfonamides, by virtue of their structural similarity, competitively inhibit the enzyme system involved in the utilization of this substrate. This hypothesis received its most important confirmation by the discovery that *p*-aminobenzoate is a precursor in the biosynthesis of folic acid and other cell constituents. Recognition of the importance of the principle of competitive inhibition as an explanation for the mechanism of action of the sulfonamides stimulated a search for analogues of other known bacterial factors. As a result a large number of structural analogues which inhibit the growth of microorganisms in specific ways have been discovered. Some examples are the folic acid and purine antagonists that have been used in cancer chemotherapy, and nicotinic acid, amino acid, and amine analogues. The list of such analogues which are becoming available is constantly expanding and it can be said with

considerable confidence that, both from the practical as well as from the theoretical point of view, their use has led to a better understanding of the highly complex machinery of the living cell.

Competition between structurally allied substances for receptor sites is a well-recognized principle in the development of chemotherapy today, and among the outstanding examples which might be mentioned are the anticholinesterases and the antihistamines. It is, however, recognized also that a structural analogue may have features in common with those of substrates for different enzymes, or of substances attached to different receptor sites and may, therefore, produce multiple effects in the cell. Such behavior is exemplified by Benzedrine (or phenylisopropylamine). Thus, Benzedrine competitively inhibits amine oxidation in brain (21), and it was suggested early that this suppression of amine oxidase by a structural analogue of its substrate was concerned with the known effects of Benzedrine on the nervous system. Later work, however, showed that the affinity of this drug was even greater for another enzyme, viz., choline oxidase (22), than for amine oxidase. Perhaps the most recent examples of *in vivo* multiple effects of the most serious nature have been the results observed following thalidomide administration to pregnant mothers in many parts of the world. Pharmacological effects of a drug may thus be dependent upon its affinity for more than one enzyme or receptor site.

It has been recognized also that a structural analogue for a given system may be first converted by the cell into a new substance which is the true inhibitor of an observed metabolic process. Thus, the nicotinamide analogue acetylpyridine leads to the formation of a "false" nicotinamide adenine dinucleotide, azaguanine is first incorporated into a nucleotide, and fluoroacetate leads to the formation of fluorocitrate which is the aconitase inhibitor, to mention only a few. Details of many of these phenomena that have a direct bearing on modern concepts of metabolic inhibition will be found in the various chapters of "Metabolic Inhibitors."

THE FUTURE

There seems to be little doubt, when the general field of metabolic inhibition is contemplated, that the role of metabolic inhibitors in the direct control of disease is undergoing serious assessment at the present time. The manner in which inhibitors act, and a firm knowledge of the underlying principles concerning their activities, will provide the means in the future for the development of new drugs with greater potency and specificity. The recognition of the importance of feedback mechanisms, whereby products of enzymic reactions control the rates of their own synthesis, or of cases where a metabolite of one enzymic reaction sequence is also a com-

petitive inhibitor of another, separate but related, sequence is an important step forward in our understanding of cellular reaction processes. An appreciation of the properties of metabolic inhibitors drawn from a great variety of enzyme studies is vital for work which is expected to lead to further understanding of abnormal cell growth, for the development of antitumor agents, for obtaining greater knowledge of genetic relationships to disease conditions, and for the exploration of growth processes as distinct from static metabolic states.

A relatively new field in the realms of biochemistry and physiology is emerging from the recent work on transport carriers across cell membranes. Here again, a knowledge of the effects of structural analogues and other types of metabolic inhibitors on the specific processes governing the activity of such carriers is of paramount importance in the development of experimental approaches to problems of this type. This field promises to be as crucial in future work on the control of cell behavior as knowledge of specific inhibitory phenomena of isolated enzyme systems has been in bringing us to the present stage of understanding.

EDITORIAL NOTES AND ACKNOWLEDGMENTS

We are well aware that, even though we have tried to produce a truly comprehensive treatise, gaps still exist and attempts will be made at a later date to close these. We have attempted to avoid excessive overlap between chapters and duplication of material but have not demanded rigorous shortening of articles since it is our firm belief that authors should be allowed to express their own opinions. In the interest of encouraging original thought and further research we have not sought to alter individual conclusions even though they may differ from those of other authors. The disparity in the lengths of the contributions has been inevitable since we have favored an individualistic approach to each assignment.

The Editors acknowledge with gratitude the efforts of the many authors who have devoted so much of their time to the composition of their chapters for both Volumes I and II of "Metabolic Inhibitors" and they thank Dr. R. M. Johnstone for the careful compilation of the all important subject index. Permission of various publishers and authors to reproduce different figures in the text of "Metabolic Inhibitors" is also gratefully acknowledged.

Ottawa, Ontario
Montreal, Quebec
Canada
April, 1963

R. M. HOCHSTER
J. H. QUASTEL

REFERENCES

1. L. Massart, in "The Enzymes" (J. B. Sumner and K. Myrbäck, eds.), Vol. 1, Part 1, p. 307. Academic Press, New York 1950.
2. R. A. Alberty, *Advances in Enzymol.* **17**, 1 (1956).
3. K. L. Laidler, "The Chemical Kinetics of Enzyme Action," p. 55 ff. Oxford Univ. Press (Clarendon), London and New York, 1958.
4. M. Dixon and E. C. Webb, "Enzymes," Academic Press, New York, 1958.
5. J. M. Reiner, "Behavior of Enzyme Systems: An Analysis of Kinetics and Mechanism." Burgess, Minneapolis, Minnesota, 1959.
6. H. L. Segal, in "The Enzymes" (P. D. Boyer, H. A. Lardy, and K. Myrbäck, eds.), 2nd Edition, Vol. 1, p. 1. Academic Press, New York, 1959.
7. J. Z. Hearon, S. A. Bernhard, S. L. Friess, D. J. Botts, and M. F. Morales, in "The Enzymes" (P. D. Boyer, H. A. Lardy, and K. Myrbäck, eds.), 2nd Edition, Vol. 1, p. 49. Academic Press, New York, 1959.
8. J. T. Wong and C. S. Hanes, *Can. J. Biochem. Physiol.* **40**, 763 (1962).
9. P. Fildes, D. D. Woods, H. McIlwain, T. S. Work, H. W. Ryden, and F. L. Rose, *Proc. Roy. Soc. (London)* **B136**, 147 (1949).
10. V. R. Potter and C. Heidelberger, *Physiol. Revs.* **30**, 487 (1950).
11. R. O. Roblin, *Chem. Eng. News* **27**, 3624 (1949); *Ann. Rev. Biochem.* **23**, 501 (1954).
12. D. W. Woolley, "A Study of Antimetabolites." Wiley, New York, 1952.
13. J. H. Quastel, in "Enzymes: Units of Biological Structure and Function" (O. H. Gaebler, ed.), p. 523. Academic Press, New York, 1956.
14. J. H. Quastel and W. R. Wooldridge, *Biochem. J.* **22**, 689 (1928).
15. J. H. Quastel, *J. Hyg.* **28**, 139 (1928).
16. J. H. Quastel, in "Activation et Structure des Molecules" (Réunion intern. de chim. phys.), p. 528. Presses Universitaires, Paris, 1929.
17. J. H. Quastel and W. R. Wooldridge, *Biochem. J.* **23**, 115 (1929).
18. A. Szent-Györgyi, *Z. physiol. Chem. Hoppe-Seylers* **244**, 105 (1936).
19. H. A. Krebs, *Advances in Enzymol.* **3**, 191 (1943).
20. D. D. Woods, *Brit. J. Exptl. Pathol.* **21**, 74 (1940).
21. P. J. G. Mann and J. H. Quastel, *Biochem. J.* **34**, 414 (1940).
22. J. S. Colter and J. H. Quastel, *Arch. Biochem. Biophys.* **41**, 305 (1952).

Contents

LIST OF CONTRIBUTORS.....	v
PREFACE AND INTRODUCTION.....	vii
CONTENTS OF VOLUME II.....	xix

CHAPTER 1

Amino Acid Analogues

WILLIAM SHIVE and CHARLES G. SKINNER

I. Introduction.....	2
II. Amino Acid Antagonists.....	3
III. Antagonisms among Amino Acids Essential for Protein Synthesis.....	26
IV. Biological Studies Involving Amino Acid Inhibitors.....	31
References.....	58

CHAPTER 2

Polypeptides and Proteins as Inhibitors

EDWARD J. MODEST, GEORGE E. FOLEY, and SIDNEY FARBER

I. Introduction.....	76
II. Polypeptide Antibiotics.....	76
III. Natural Protein and Polypeptide Inhibitors.....	95
IV. Synthetic Poly- α -Amino Acids.....	104
V. Analogues of the Polypeptide and Protein Hormones.....	107
VI. Modified Enzymes as Inhibitors.....	111
VII. Miscellaneous Di- and Tripeptide Inhibitors.....	113
VIII. Concluding Remarks.....	116
References.....	118

CHAPTER 3

Hexose and Pentose Analogues

R. M. HOCHSTER

I. Introduction.....	131
II. Hexoses.....	134
III. Pentoses.....	147
IV. Conclusions.....	149
References.....	150

CHAPTER 4

Fatty Acids and Their Analogues

P. G. SCHOLEFIELD

I. Metabolic Inhibitory Effects of Normal Fatty Acids.....	154
II. Metabolic Inhibitory Effects of Acyl Coenzyme A Derivatives.....	160
III. Fatty Acid Analogues.....	165
References.....	169

CHAPTER 5

Phospholipids

J. B. DAVENPORT

I. Phospholipid Catabolism.....	174
II. Phospholipid Synthesis.....	197
III. Ion Transport and Phospholipid Metabolism.....	204
IV. Alternative Pathway for Lecithin Synthesis; Transmethylation Involving Glycerophosphatides.....	206
V. Conclusions.....	209
References.....	211

CHAPTER 6

Purine Analogues

GEORGE H. HITCHINGS and GERTRUDE B. ELION

I. Introduction.....	215
II. Cellular Multiplication.....	218
III. Effects in the Whole Organism.....	222
IV. Effects on Function.....	225
V. Biochemical Effects.....	226
VI. Conclusion.....	232
References.....	232

CHAPTER 7

Pyrimidine Analogues

R. W. BROCKMAN and E. P. ANDERSON

I. Introduction.....	239
II. Biosynthesis and Metabolic Functions of Pyrimidine Nucleotides.....	240
III. Pyrimidine Analogues.....	246
IV. Other Inhibitors of Pyrimidine Nucleotide Biosynthesis.....	273
References.....	277

CHAPTER 8

Nucleic Acids and Nucleoproteins

K. A. O. ELLEM and J. S. COLTER

I. Introduction.....	287
II. The Nucleic Acids: Their Role in the Control of Cellular Metabolism.....	288
III. Virus Infection.....	297
References.....	308

CHAPTER 9

Inhibition of Amino Acid Decarboxylases

WILLIAM GILBERT CLARK

I. Introduction.....	316
II. Pyridoxal Kinase.....	318
III. Apoenzyme-Coenzyme Dissociation.....	319
IV. Transport, Uptake, Binding, Release.....	320
V. Inanition.....	322
VI. Tissue Damage, Growth, Neoplasms, Organectomy.....	322
VII. Apoenzyme Synthesis.....	323
VIII. Inhibition by Apoenzyme Antibody.....	326
IX. Metals, Chelators, and Metal Complexers.....	327
X. Cyanide.....	330
XI. Pyridoxal-5-Phosphate (Codecarboxylase), Vitamin B ₆ , B ₆ -Deficiency, B ₆ -Antagonists.....	331
XII. Activators, Stabilizers, and Cofactors Other Than B ₆ -PO ₄	337
XIII. Carbonyl Reagents and Inhibitors Acting on Coenzyme Other Than Cyanide, Substrate Analogues, and Pyridoxine Antagonists.....	339
XIV. Hormones.....	346
XV. Miscellaneous.....	354
XVI. Substrate Analogues.....	356
References.....	366

CHAPTER 10

**Inhibitors, Antagonists, and Inactivators in the Etiology of
Diabetes Mellitus in Man**

I. ARTHUR MIRSKY

I. Introduction.....	383
II. Insulinogenesis.....	384
III. Release of Insulin.....	384
IV. Impairment of Insulinogenesis.....	384
V. Impairment of Insulin Release.....	386
VI. Impairment in Transport of Insulin.....	387
VII. Inhibitors of Insulin.....	389
VIII. Impairment of Insulin Receptor Sites.....	393
IX. Antagonists of Action of Insulin.....	395

X.	Excretion of Insulin.....	396
XI.	Degradation of Insulin.....	397
XII.	Inhibitors of Insulin Degradation.....	398
XIII.	Summary.....	401
	References.....	402

CHAPTER 11

Antagonists and Inhibitors of the Fat-soluble Vitamins

J. GREEN

I.	Vitamin A.....	408
II.	Vitamin D.....	416
III.	Vitamin E.....	420
IV.	Vitamin K.....	428
	References.....	438

CHAPTER 12

Antimetabolites of the Water-soluble Vitamins

D. W. WOOLLEY

I.	General Principles of Antimetabolite Action.....	445
II.	Antimetabolites of Water-soluble Vitamins.....	455
	References.....	475

CHAPTER 13

Sulfonamides and Folic Acid Antagonists

THOMAS H. JUKES and HARRY P. BROQUIST

I.	Introduction.....	481
II.	Sulfonamides.....	485
III.	Folic Acid in Enzymic Reactions.....	492
IV.	Folic Acid Antagonists.....	501
	References.....	529

CHAPTER 14

Throxine Analogues

S. B. BARKER

I. Introduction.....	535
II. Techniques of Evaluating Thyroxine Inhibitors.....	538
III. Early Studies of Compounds Related to Diiodotyrosine.....	541
IV. Ethers of Diiodotyrosine and Related Compounds.....	543
V. Derivatives of Diiodohydroxybenzoic Acid.....	546
VI. Iodinated Phenoxyacetic Acids.....	547
VII. Partially Iodinated Thyronines and Related Compounds.....	548
VIII. General Survey of Inhibitory Structures.....	556
References	564

CHAPTER 15

Inhibitors of Steroid Actions and Cholesterol and Steroid Biosynthesis

R. I. DORFMAN

I. Introduction.....	567
II. Inhibition of Estrogenic Activity.....	568
III. Inhibition of Androgenic Activity.....	576
IV. Inhibition of Corticoid Activity.....	577
V. Inhibition of Steroid Biosynthesis.....	578
VI. Inhibition of Cholesterol Biosynthesis.....	579
References	583
AUTHOR INDEX.....	587
SUBJECT INDEX.....	641